Tissue-resident memory T cell

Last updated

Tissue-resident memory T cells or TRM cells represent a subset of a long-lived memory T cells that occupies epithelial, mucosal and other tissues (skin, mucosa, lung, brain, pancreas, gastrointestinal tract) without recirculating. TRM cells are transcriptionally, phenotypically and functionally distinct from central memory (TCM) and effector memory (TEM) T cells which recirculate between blood, the T cell zones of secondary lymphoid organ, lymph and nonlymphoid tissues. Moreover, TRM cells consist of diverse populations both between tissues and within a single tissue. TRM cells provide protection against infection in extralymphoid tissues. [1] [2] [3]

Contents

Phenotype

Three cell surface markers that has been associated with TRM are CD69, CD49a, and CD103. CD69 suppresses response to the S1P chemoattractant from blood and lymph and prevents TRM cells from exiting peripheral tissue. [4] [5] CD49a mediates tissue residency directly and marks cells with the most effector-like capabilities including IFN-gamma production and the ability to directly kill infected cells. [6] [7] CD103 is expressed by many CD8+ TRM cells and rarely by CD4+ TRM cells, usually in conjunction with CD49a. [8] TRM cells have tissue residency-promoting transcriptional signature with features specific to individual tissues and features necessary for long-term survival in these tissues. [9]

Development

TRM cells develop from circulating effector memory T cell precursors in response to antigen. The main role in formation of TRM cells has CD103 and expression of this integrin is dependent on the cytokine TGF-β. CD8+ effector T cells that lack TGF-β fail to upregulate CD103, and subsequently do not differentiate into TRM cells. The important role in development of TRM cells have various cytokines that support TRM cell formation and survival. For example, homeostatic cytokine IL-15, pro-inflammatory cytokines such as IL-12 and IL-18, and barrier cytokines such as IL-33. [19] [20] [21] Also, generation of CD103+ TRM cells requires low expression of Eomes and T-bet transcription factors. [17]

Shortly after antigen-specific response in the non-lymphoid tissue, infected tissue is occupied by CD8+ effector-stage T cells (TEFF). These cells present early in the tissue have higher expression of some genes typical for TRM and at the peak of the T cell response, local T cell population expresses more than 90% of the TRM gene signature. [22] This shows that differentiation process of TRM cells starts early during immune response. [9]

Function

TRM cells reside in many tissues that create barriers against outside environment and thus provide defense against repeatedly incoming pathogens. In the skin, lung, brain, and vagina TRM cells are required to provide immediate rapid control of re-infection. CD4+ TRM cells provide better protection against repeated infection with influenza in comparison with circulating memory CD4+ T cells. [23] [24] Moreover, CD8+ TRM cells also play role in the protection against malignancies. [5] TRM cells express granzyme B which helps limit the spread of pathogens at the site of infection. Also, phenotypic and functional diversity is not only in TRM from different tissues, but it could be found in various TRM subsets within the same tissue. For example, CD49a distinguishes CD8+ TRM subsets with different functions. TRM cells positive for this marker produce perforin and IFNɤ. On the other side, TRM without CD49a expression produce IL-17. [25] IFNɤ production depends on the localization of TRM in the tissue niche. CD8+ TRM in mouse airways produce significant IFNɤ in comparison to parenchymal CD8+ TRM cells. [26] [16] After reactivation, TRM cells undergo rapid proliferation in situ. Increase in TRM numbers after repeated exposure to antigens is not derived just from existing TRM, but circulating T cells contribute to the generation and higher numbers of TRM, too. [16] Also, not every TRM express CD69 and CD103 what support phenotypic heterogeneity of TRM cells. [18] TRM cells are able to activate innate and adaptive leukocytes to protect the host. [27] [2] [28] [29] Cooperation of TRM cells with other memory T cell populations provide tissue surveillance and clearance of the infections. [30] [31] [12]

Potential of CD8+ TRM cells in cancer immunotherapy

Cytotoxic CD8+ T lymphocytes are able to recognize malignant cells. Production of neoantigens by tumour cells can lead to peptides which are presented to CD8+ T cells bound to MHC I. After antigen recognition, CD8+ T cells destroy tumor cells using IFN-ɤ, TNF-α, granzyme B and perforin. However, malignant cells can avoid this elimination by various mechanisms such as the loss of MHC I molecule, induction of anti-inflammatory tumor micro-environment, inhibition of T cell function, upregulation of ligands whose interactions with CD8+ T cell receptors results in their suppression etc. Immune checkpoint therapy and tumor-infiltrating lymphocytes (TIL) therapy are cancer immunotherapy strategies whose principle lies in suppression of tumor cell inhibitory pathways or in introduction of expanded CD8+ T cells. Whereas large fraction of TILs are TRM cells, they are candidates for solid cancer immunotherapy. [5]

TRM cells infiltrated in tumors have protective role and are associated with good clinical results in various cancer types, but not in pancreatic cancer. They have decreased expression of IFN-ɤ, TNF-α and IL-2 in comparison with circulating T cells in melanoma patients what suggest different mechanism for tumor growth control. Upregulation of granzyme A and granzyme B was found in TRM cells in lung carcinoma patients. However, in TRM cells are also upregulated immune checkpoint receptors. This suggests, that most of the tumor TRM show an exhausted phenotype which may be saved by immune checkpoint inhibitor therapies. Nonidentical tumors may contain different TRM populations. [5]

Role in disease pathogenesis

Autoreactive TRM cells and reduced ratio or activity of regulatory T cells (Tregs) which protects body from autoimmunity by securing self-tolerance may induce autoimmune diseases sucha as vitiligo, cutaneous lupus erythematosus, psoriasis, alopecia areata, cicatricial alopecia,multiple sclerosis, lupus nephritis, rheumatoid arthritis and autoimmune hepatitis. [12] [32]

Vitiligo

Vitiligo is an autoimmune skin disease with white spots phenotype. CD8+ T lymphocytes destroy melanocytes in some parts of the skin what manifest like white spots on the skin. Multiple genes as well as environment play role in developing vitiligo and migration of CD8+ T cells correlates with the state of disease. 80% of autoreactive CD8+ T cells which are specific towards melanocyte self-antigens express CD69 or CD69 and CD103 TRM markers. There is also higher number of CD49a+ CD8+ CD103+ T cells with cytotoxic potential in epiderma and derma of the vitiligo patients in comparison with healthy skin. Treatment of vitiligo lies in inhibition of JAK/STAT signaling pathway using JAK inhibitors. TRM cells have reduced IFNɤ production and white spots on skin disappear. However, the treatment can not be stopped, because white spots will appear again. [12]

Cutaneous Lupus Erythematosus (CLE)

CLE is another autoimmune skin disease with several subtypes. Common feature is interface dermatitis or inflammation at the dermal-epidermal junction. Again, contribution of genetic and environment factors lead to the development of CLE. It is not really clear what is the specificity of the T cell causing CLE in the skin, but some studies showed T cells reactive to nucleosomes/histones. Except aberrant T cell signaling which conduces to the pathogenesis of CLE, increased presence of TRM was also found in the skin of CLE patients refractory to antimalarials. Treatment lies in JAK/STAT inhibitors, but can not be stopped, because skin lessions will appear again. [12]

Related Research Articles

<span class="mw-page-title-main">Autoimmunity</span> Immune response against an organisms own healthy cells

In immunology, autoimmunity is the system of immune responses of an organism against its own healthy cells, tissues and other normal body constituents. Any disease resulting from this type of immune response is termed an "autoimmune disease". Prominent examples include celiac disease, diabetes mellitus type 1, Henoch–Schönlein purpura, systemic lupus erythematosus, Sjögren syndrome, eosinophilic granulomatosis with polyangiitis, Hashimoto's thyroiditis, Graves' disease, idiopathic thrombocytopenic purpura, Addison's disease, rheumatoid arthritis, ankylosing spondylitis, polymyositis, dermatomyositis, and multiple sclerosis. Autoimmune diseases are very often treated with steroids.

<span class="mw-page-title-main">Dendritic cell</span> Accessory cell of the mammalian immune system

A dendritic cell (DC) is an antigen-presenting cell of the mammalian immune system. A DC's main function is to process antigen material and present it on the cell surface to the T cells of the immune system. They act as messengers between the innate and adaptive immune systems.

<span class="mw-page-title-main">T cell</span> White blood cells of the immune system

T cells are one of the important types of white blood cells of the immune system and play a central role in the adaptive immune response. T cells can be distinguished from other lymphocytes by the presence of a T-cell receptor (TCR) on their cell surface.

<span class="mw-page-title-main">T helper cell</span> Type of immune cell

The T helper cells (Th cells), also known as CD4+ cells or CD4-positive cells, are a type of T cell that play an important role in the adaptive immune system. They aid the activity of other immune cells by releasing cytokines. They are considered essential in B cell antibody class switching, breaking cross-tolerance in dendritic cells, in the activation and growth of cytotoxic T cells, and in maximizing bactericidal activity of phagocytes such as macrophages and neutrophils. CD4+ cells are mature Th cells that express the surface protein CD4. Genetic variation in regulatory elements expressed by CD4+ cells determines susceptibility to a broad class of autoimmune diseases.

Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Immunotherapy is under preliminary research for its potential to treat various forms of cancer.

Cross-presentation is the ability of certain professional antigen-presenting cells (mostly dendritic cells) to take up, process and present extracellular antigens with MHC class I molecules to CD8 T cells (cytotoxic T cells). Cross-priming, the result of this process, describes the stimulation of naive cytotoxic CD8+ T cells into activated cytotoxic CD8+ T cells. This process is necessary for immunity against most tumors and against viruses that infect dendritic cells and sabotage their presentation of virus antigens. Cross presentation is also required for the induction of cytotoxic immunity by vaccination with protein antigens, for example, tumour vaccination.

Gut-associated lymphoid tissue (GALT) is a component of the mucosa-associated lymphoid tissue (MALT) which works in the immune system to protect the body from invasion in the gut.

Memory T cells are a subset of T lymphocytes that might have some of the same functions as memory B cells. Their lineage is unclear.

Immune tolerance, also known as immunological tolerance or immunotolerance, refers to the immune system's state of unresponsiveness to substances or tissues that would otherwise trigger an immune response. It arises from prior exposure to a specific antigen and contrasts the immune system's conventional role in eliminating foreign antigens. Depending on the site of induction, tolerance is categorized as either central tolerance, occurring in the thymus and bone marrow, or peripheral tolerance, taking place in other tissues and lymph nodes. Although the mechanisms establishing central and peripheral tolerance differ, their outcomes are analogous, ensuring immune system modulation.

<span class="mw-page-title-main">Intraepithelial lymphocyte</span>

Intraepithelial lymphocytes (IEL) are lymphocytes found in the epithelial layer of mammalian mucosal linings, such as the gastrointestinal (GI) tract and reproductive tract. However, unlike other T cells, IELs do not need priming. Upon encountering antigens, they immediately release cytokines and cause killing of infected target cells. In the GI tract, they are components of gut-associated lymphoid tissue (GALT).

In immunology, peripheral tolerance is the second branch of immunological tolerance, after central tolerance. It takes place in the immune periphery. Its main purpose is to ensure that self-reactive T and B cells which escaped central tolerance do not cause autoimmune disease. Peripheral tolerance can also serve a purpose in preventing an immune response to harmless food antigens and allergens.

<span class="mw-page-title-main">CD69</span> Human lectin protein

CD69 is a human transmembrane C-Type lectin protein encoded by the CD69 gene. It is an early activation marker that is expressed in hematopoietic stem cells, T cells, and many other cell types in the immune system. It is also implicated in T cell differentiation as well as lymphocyte retention in lymphoid organs.

Gamma delta T cells are T cells that have a γδ T-cell receptor (TCR) on their surface. Most T cells are αβ T cells with TCR composed of two glycoprotein chains called α (alpha) and β (beta) TCR chains. In contrast, γδ T cells have a TCR that is made up of one γ (gamma) chain and one δ (delta) chain. This group of T cells is usually less common than αβ T cells. Their highest abundance is in the gut mucosa, within a population of lymphocytes known as intraepithelial lymphocytes (IELs).

The following outline is provided as an overview of and topical guide to immunology:

Innate lymphoid cells (ILCs) are the most recently discovered family of innate immune cells, derived from common lymphoid progenitors (CLPs). In response to pathogenic tissue damage, ILCs contribute to immunity via the secretion of signalling molecules, and the regulation of both innate and adaptive immune cells. ILCs are primarily tissue resident cells, found in both lymphoid, and non- lymphoid tissues, and rarely in the blood. They are particularly abundant at mucosal surfaces, playing a key role in mucosal immunity and homeostasis. Characteristics allowing their differentiation from other immune cells include the regular lymphoid morphology, absence of rearranged antigen receptors found on T cells and B cells, and phenotypic markers usually present on myeloid or dendritic cells.

<span class="mw-page-title-main">Bronchus-associated lymphoid tissue</span>

Bronchus-associated lymphoid tissue (BALT) is a tertiary lymphoid structure. It is a part of mucosa-associated lymphoid tissue (MALT), and it consists of lymphoid follicles in the lungs and bronchus. BALT is an effective priming site of the mucosal and systemic immune responses.

Memory T cell inflation phenomenon is the formation and maintenance of a large population of specific CD8+ T cells in reaction to cytomegalovirus (CMV) infection.

<span class="mw-page-title-main">Laura Mackay</span> Australian scientist

Laura K. Mackay is an Australian immunologist and Professor of Immunology at the University of Melbourne. Mackay is the Theme Leader in Immunology and Laboratory Head at the Peter Doherty Institute for Infection and Immunity. In 2022, she was the youngest Fellow elected to the Australian Academy of Health and Medical Sciences.

Thomas S. Kupper is an American physician, academic, and clinician. His work with clinical and research experience spans dermatology, cutaneous oncology, and immunology. He is the Thomas B. Fitzpatrick Professor at Harvard Medical School, and chairs the Departments of Dermatology at Brigham and Women's Hospital. He also leads the Cutaneous Oncology Disease Center at the Dana Farber Cancer Institute.

Whole-cell vaccines are a type of vaccine that has been prepared in the laboratory from entire cells. Such vaccines simultaneously contain multiple antigens to activate the immune system. They induce antigen-specific T-cell responses.

References

  1. ↑ Schenkel JM, Masopust D (December 2014). "Tissue-resident memory T cells". Immunity. 41 (6): 886–97. doi:10.1016/j.immuni.2014.12.007. PMC   4276131 . PMID   25526304.
  2. 1 2 Shin H, Iwasaki A (September 2013). "Tissue-resident memory T cells". Immunological Reviews. 255 (1): 165–81. doi:10.1111/imr.12087. PMC   3748618 . PMID   23947354.
  3. ↑ Reilly, Emma C.; Sportiello, Mike; Emo, Kris Lambert; Amitrano, Andrea M.; Jha, Rakshanda; Kumar, Ashwin B. R.; Laniewski, Nathan G.; Yang, Hongmei; Kim, Minsoo; Topham, David J. (2021-09-09). "CD49a Identifies Polyfunctional Memory CD8 T Cell Subsets that Persist in the Lungs After Influenza Infection". Frontiers in Immunology. 12. doi: 10.3389/fimmu.2021.728669 . ISSN   1664-3224. PMC   8462271 . PMID   34566986.
  4. ↑ Mackay, Laura K.; Braun, Asolina; Macleod, Bethany L.; Collins, Nicholas; Tebartz, Christina; Bedoui, Sammy; Carbone, Francis R.; Gebhardt, Thomas (2015-03-01). "Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention". Journal of Immunology. 194 (5): 2059–2063. doi: 10.4049/jimmunol.1402256 . ISSN   1550-6606. PMID   25624457. S2CID   22798755.
  5. 1 2 3 4 Beumer-Chuwonpad, Ammarina; Taggenbrock, Renske L. R. E.; Ngo, T. An; van Gisbergen, Klaas P. J. M. (2021-08-28). "The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer". Cells. 10 (9): 2234. doi: 10.3390/cells10092234 . ISSN   2073-4409. PMC   8465847 . PMID   34571883.
  6. ↑ Ray, Steven J.; Franki, Suzanne N.; Pierce, Robert H.; Dimitrova, Snezhana; Koteliansky, Victor; Sprague, Andrew G.; Doherty, Peter C.; de Fougerolles, Antonin R.; Topham, David J. (2004-02-17). "The collagen binding alpha1beta1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection". Immunity. 20 (2): 167–179. doi: 10.1016/s1074-7613(04)00021-4 . ISSN   1074-7613. PMID   14975239.
  7. ↑ Reilly, Emma C.; Sportiello, Mike; Emo, Kris Lambert; Amitrano, Andrea M.; Jha, Rakshanda; Kumar, Ashwin B. R.; Laniewski, Nathan G.; Yang, Hongmei; Kim, Minsoo; Topham, David J. (2021). "CD49a Identifies Polyfunctional Memory CD8 T Cell Subsets that Persist in the Lungs After Influenza Infection". Frontiers in Immunology. 12: 728669. doi: 10.3389/fimmu.2021.728669 . ISSN   1664-3224. PMC   8462271 . PMID   34566986.
  8. ↑ Kumar BV, Ma W, Miron M, Granot T, Guyer RS, Carpenter DJ, et al. (September 2017). "Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites". Cell Reports. 20 (12): 2921–2934. doi:10.1016/j.celrep.2017.08.078. PMC   5646692 . PMID   28930685.
  9. 1 2 Kok, Lianne; Masopust, David; Schumacher, Ton N. (2021-09-03). "The precursors of CD8+ tissue resident memory T cells: from lymphoid organs to infected tissues". Nature Reviews. Immunology. 22 (5): 283–293. doi:10.1038/s41577-021-00590-3. ISSN   1474-1741. PMC   8415193 . PMID   34480118.
  10. ↑ Weisberg, Stuart P.; Carpenter, Dustin J.; Chait, Michael; Dogra, Pranay; Gartrell-Corrado, Robyn D.; Chen, Andrew X.; Campbell, Sean; Liu, Wei; Saraf, Pooja; Snyder, Mark E.; Kubota, Masaru (2019-12-17). "Tissue-Resident Memory T Cells Mediate Immune Homeostasis in the Human Pancreas through the PD-1/PD-L1 Pathway". Cell Reports. 29 (12): 3916–3932.e5. doi:10.1016/j.celrep.2019.11.056. ISSN   2211-1247. PMC   6939378 . PMID   31851923.
  11. ↑ Sathaliyawala, Taheri; Kubota, Masaru; Yudanin, Naomi; Turner, Damian; Camp, Philip; Thome, Joseph J. C.; Bickham, Kara L.; Lerner, Harvey; Goldstein, Michael; Sykes, Megan; Kato, Tomoaki (2013-01-24). "Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets". Immunity. 38 (1): 187–197. doi:10.1016/j.immuni.2012.09.020. ISSN   1097-4180. PMC   3557604 . PMID   23260195.
  12. 1 2 3 4 5 6 7 Ryan, Grace E.; Harris, John E.; Richmond, Jillian M. (2021). "Resident Memory T Cells in Autoimmune Skin Diseases". Frontiers in Immunology. 12: 652191. doi: 10.3389/fimmu.2021.652191 . ISSN   1664-3224. PMC   8128248 . PMID   34012438.
  13. ↑ Richmond, Jillian M.; Strassner, James P.; Zapata, Lucio; Garg, Madhuri; Riding, Rebecca L.; Refat, Maggi A.; Fan, Xueli; Azzolino, Vincent; Tovar-Garza, Andrea; Tsurushita, Naoya; Pandya, Amit G. (2018-07-18). "Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo". Science Translational Medicine. 10 (450): eaam7710. doi:10.1126/scitranslmed.aam7710. ISSN   1946-6242. PMC   6495055 . PMID   30021889.
  14. ↑ Pan, Youdong; Tian, Tian; Park, Chang Ook; Lofftus, Serena Y.; Mei, Shenglin; Liu, Xing; Luo, Chi; O'Malley, John T.; Gehad, Ahmed; Teague, Jessica E.; Divito, Sherrie J. (2017-03-09). "Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism". Nature. 543 (7644): 252–256. Bibcode:2017Natur.543..252P. doi:10.1038/nature21379. ISSN   1476-4687. PMC   5509051 . PMID   28219080.
  15. ↑ Mackay, Laura K.; Rahimpour, Azad; Ma, Joel Z.; Collins, Nicholas; Stock, Angus T.; Hafon, Ming-Li; Vega-Ramos, Javier; Lauzurica, Pilar; Mueller, Scott N.; Stefanovic, Tijana; Tscharke, David C. (December 2013). "The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin". Nature Immunology. 14 (12): 1294–1301. doi:10.1038/ni.2744. hdl: 1885/12900 . ISSN   1529-2916. PMID   24162776. S2CID   32642573.
  16. 1 2 3 Paik, Daniel H.; Farber, Donna L. (February 2021). "Anti-viral protective capacity of tissue resident memory T cells". Current Opinion in Virology. 46: 20–26. doi:10.1016/j.coviro.2020.09.006. ISSN   1879-6265. PMC   7979430 . PMID   33130326.
  17. 1 2 Yuan, Rui; Yu, Jiang; Jiao, Ziqiao; Li, Jinfei; Wu, Fang; Yan, Rongkai; Huang, Xiaojie; Chen, Chen (2021). "The Roles of Tissue-Resident Memory T Cells in Lung Diseases". Frontiers in Immunology. 12: 710375. doi: 10.3389/fimmu.2021.710375 . ISSN   1664-3224. PMC   8542931 . PMID   34707601.
  18. 1 2 Mueller, Scott N.; Mackay, Laura K. (February 2016). "Tissue-resident memory T cells: local specialists in immune defence". Nature Reviews. Immunology. 16 (2): 79–89. doi:10.1038/nri.2015.3. ISSN   1474-1741. PMID   26688350. S2CID   3155731.
  19. ↑ Shin H (February 2018). "Formation and function of tissue-resident memory T cells during viral infection". Current Opinion in Virology. 28: 61–67. doi:10.1016/j.coviro.2017.11.001. PMID   29175730.
  20. ↑ Mackay LK, Rahimpour A, Ma JZ, Collins N, Stock AT, Hafon ML, et al. (December 2013). "The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin". Nature Immunology. 14 (12): 1294–301. doi:10.1038/ni.2744. hdl: 1885/12900 . PMID   24162776. S2CID   32642573.
  21. ↑ Casey KA, Fraser KA, Schenkel JM, Moran A, Abt MC, Beura LK, et al. (May 2012). "Antigen-independent differentiation and maintenance of effector-like resident memory T cells in tissues". Journal of Immunology. 188 (10): 4866–75. doi:10.4049/jimmunol.1200402. PMC   3345065 . PMID   22504644.
  22. ↑ Milner, J. Justin; Toma, Clara; Yu, Bingfei; Zhang, Kai; Omilusik, Kyla; Phan, Anthony T.; Wang, Dapeng; Getzler, Adam J.; Nguyen, Toan; Crotty, Shane; Wang, Wei (2017-12-14). "Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours". Nature. 552 (7684): 253–257. Bibcode:2017Natur.552..253M. doi:10.1038/nature24993. ISSN   1476-4687. PMC   5747964 . PMID   29211713.
  23. ↑ Teijaro, John R.; Turner, Damian; Pham, Quynh; Wherry, E. John; Lefrançois, Leo; Farber, Donna L. (2011-12-01). "Cutting edge: Tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection". Journal of Immunology. 187 (11): 5510–5514. doi:10.4049/jimmunol.1102243. ISSN   1550-6606. PMC   3221837 . PMID   22058417.
  24. ↑ Raphael, Itay; Joern, Rachel R.; Forsthuber, Thomas G. (2020-02-25). "Memory CD4+ T Cells in Immunity and Autoimmune Diseases". Cells. 9 (3): E531. doi: 10.3390/cells9030531 . ISSN   2073-4409. PMC   7140455 . PMID   32106536.
  25. ↑ Wu H, Liao W, Li Q, Long H, Yin H, Zhao M, Chan V, Lau CS, Lu Q (July 2018). "Pathogenic role of tissue-resident memory T cells in autoimmune diseases". Autoimmunity Reviews. 17 (9): 906–911. doi:10.1016/j.autrev.2018.03.014. PMID   30005862. S2CID   51625032.
  26. ↑ McMaster, Sean R.; Wilson, Jarad J.; Wang, Hong; Kohlmeier, Jacob E. (2015-07-01). "Airway-Resident Memory CD8 T Cells Provide Antigen-Specific Protection against Respiratory Virus Challenge through Rapid IFN-γ Production". Journal of Immunology. 195 (1): 203–209. doi:10.4049/jimmunol.1402975. ISSN   1550-6606. PMC   4475417 . PMID   26026054.
  27. ↑ Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR (May 2009). "Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus". Nature Immunology. 10 (5): 524–30. doi:10.1038/ni.1718. PMID   19305395. S2CID   24388.
  28. ↑ Wakim LM, Woodward-Davis A, Bevan MJ (October 2010). "Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence". Proceedings of the National Academy of Sciences of the United States of America. 107 (42): 17872–9. doi: 10.1073/pnas.1010201107 . PMC   2964240 . PMID   20923878.
  29. ↑ Ariotti S, Hogenbirk MA, Dijkgraaf FE, Visser LL, Hoekstra ME, Song JY, et al. (October 2014). "T cell memory. Skin-resident memory CD8⁺ T cells trigger a state of tissue-wide pathogen alert". Science. 346 (6205): 101–5. doi:10.1126/science.1254803. PMID   25278612. S2CID   37918023.
  30. ↑ Richmond, Jillian M.; Strassner, James P.; Rashighi, Mehdi; Agarwal, Priti; Garg, Madhuri; Essien, Kingsley I.; Pell, Lila S.; Harris, John E. (April 2019). "Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo". The Journal of Investigative Dermatology. 139 (4): 769–778. doi:10.1016/j.jid.2018.10.032. ISSN   1523-1747. PMC   6431571 . PMID   30423329.
  31. ↑ Watanabe, Rei; Gehad, Ahmed; Yang, Chao; Scott, Laura L.; Teague, Jessica E.; Schlapbach, Christoph; Elco, Christopher P.; Huang, Victor; Matos, Tiago R.; Kupper, Thomas S.; Clark, Rachael A. (2015-03-18). "Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells". Science Translational Medicine. 7 (279): 279ra39. doi:10.1126/scitranslmed.3010302. ISSN   1946-6242. PMC   4425193 . PMID   25787765.
  32. ↑ Clark RA (January 2015). "Resident memory T cells in human health and disease". Science Translational Medicine. 7 (269): 269rv1. doi:10.1126/scitranslmed.3010641. PMC   4425129 . PMID   25568072.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.